Abstract
The strong CD8+ T-cell-mediated HIV-1-suppressive capacity found in a minority of HIV-infected patients in chronic infection is associated with spontaneous control of viremia. However, it is still unclear whether such capacities were also present earlier in the CD8+ T cells from non controller patients and then lost as a consequence of uncontrolled viral replication. We studied 50 patients with primary HIV-1-infection to determine whether strong CD8+ T-cell-mediated HIV suppression is more often observed at that time. Despite high frequencies of polyfunctional HIV-specific CD8+ T-cells and a strong CD4+ T-helper response, CD8+ T-cells from 48 patients lacked strong HIV-suppressive capacities ex vivo. This indicates that the superior HIV-suppressive capacity of CD8+ T-cells from HIV controllers is not a general characteristic of the HIV-specific CD8+ T cell response in primary HIV infection.
Publication types
-
Clinical Trial, Phase III
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Disease
-
Adult
-
CD4-Positive T-Lymphocytes / cytology
-
CD8-Positive T-Lymphocytes / immunology*
-
CD8-Positive T-Lymphocytes / virology*
-
Cells, Cultured
-
Cytokines / metabolism
-
Disease Progression
-
Female
-
HIV Infections / immunology*
-
HIV Infections / virology*
-
HIV-1 / physiology
-
Humans
-
Interleukin-2 / metabolism
-
Leukocytes, Mononuclear / metabolism
-
Male
-
Middle Aged
-
Time Factors
-
Viral Load
-
Virus Replication
Grants and funding
The ANRS 147 OPTIPRIM trial was funded by ANRS (French National Agency for Research on AIDS and Viral Hepatitis) and conducted with the support of MSD, Janssen, ViiV Healthcare and Gilead. CL received a postdoctoral fellowship from ANRS. GP is an employee of INSERM (Institut National de la Santé et de la Recherche Médicale). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.